These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27100772)

  • 41. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
    Kemp TJ; García-Piñeres A; Falk RT; Poncelet S; Dessy F; Giannini SL; Rodriguez AC; Porras C; Herrero R; Hildesheim A; Pinto LA;
    Vaccine; 2008 Jul; 26(29-30):3608-16. PubMed ID: 18541349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.
    López-Codony V; de Andrés-Pablo Á; Ferrando-Díez A; Fernández-Montolí ME; López-Querol M; Tous S; Ortega-Expósito C; Torrejón-Becerra JC; Pérez Y; Ferrer-Artola A; Sole-Sedeno JM; Grau C; Rupérez B; Saumoy M; Sánchez M; Peremiquel-Trillas P; Bruni L; Alemany L; Bosch FX; Pavón MA
    PLoS One; 2024; 19(5):e0304080. PubMed ID: 38768231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.
    Schwarz TF; Leo O
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S1-10. PubMed ID: 18653222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
    Simen-Kapeu A; Kataja V; Yliskoski M; Syrjänen K; Dillner J; Koskela P; Paavonen J; Lehtinen M
    Scand J Infect Dis; 2008; 40(9):745-51. PubMed ID: 19086247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.
    Huo Z; Bissett SL; Giemza R; Beddows S; Oeser C; Lewis DJ
    PLoS One; 2012; 7(3):e33736. PubMed ID: 22438987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.
    Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR
    J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.
    Khatun S; Akram Hussain SM; Chowdhury S; Ferdous J; Hossain F; Begum SR; Jahan M; Tabassum S; Khatun S; Karim AB
    Jpn J Clin Oncol; 2012 Jan; 42(1):36-41. PubMed ID: 22194637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-risk papillomavirus infection is associated with altered antibody responses in genital tract: non-specific responses in HPV infection.
    Bard E; Riethmuller D; Meillet D; Prétet JL; Schaal JP; Mougin C; Seillès E
    Viral Immunol; 2004; 17(3):381-9. PubMed ID: 15357904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cervical carcinoma and the vaccination experience with Cervarix].
    Berberova M
    Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670
    [No Abstract]   [Full Text] [Related]  

  • 52. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
    Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
    Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
    Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
    Huang LM; Puthanakit T; Cheng-Hsun C; Ren-Bin T; Schwarz T; Pellegrino A; Esposito S; Frenette L; McNeil S; Durando P; Rheault P; Giaquinto C; Horn M; Petry KU; Peters K; Azhar T; Hillemanns P; De Simoni S; Friel D; Pemmaraju S; Hezareh M; Thomas F; Descamps D; Folschweiller N; Struyf F
    J Infect Dis; 2017 Jun; 215(11):1711-1719. PubMed ID: 28591778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
    Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
    Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
    Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
    J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.